Biogen to Acquire Apellis for $5.6 Billion, Bolstering Immunology and Rare Disease Portfolio
Event summary
- Biogen to acquire Apellis for $41 per share in cash, totaling approximately $5.6 billion, with a contingent value right (CVR) per share for SYFOVRE® sales milestones.
- Apellis's EMPAVELI® and SYFOVRE® generated $689 million in combined net sales in 2025, with expected mid-to-high teens growth through 2028.
- Acquisition expected to bolster Biogen’s near-and long-term growth prospects, adding immediate revenue and accelerating entry into nephrology.
- Transaction expected to close in Q2 2026, with Biogen financing through a combination of cash and borrowings.
- Biogen to host investor conference call on March 31, 2026, to discuss the acquisition.
The big picture
Biogen's acquisition of Apellis represents a strategic move to enhance its growth portfolio in immunology and rare disease, adding two commercialized medicines with significant growth potential. This deal underscores Biogen's focus on expanding into nephrology and bolstering its long-term revenue and earnings growth prospects. The transaction is expected to be increasingly accretive to Biogen's non-GAAP diluted EPS starting in 2027, reflecting the company's commitment to maintaining financial flexibility for future investments.
What we're watching
- Revenue Integration
- How Biogen will integrate Apellis's commercial products into its existing portfolio and maximize their growth potential.
- Regulatory Approvals
- Whether the transaction will receive necessary regulatory approvals and close as expected in Q2 2026.
- Execution Risk
- The pace at which Biogen can leverage Apellis's talent and expertise to accelerate its nephrology capabilities and launch readiness for felzartamab.
Related topics